Skip to main navigation

Skip to Content

About Us
- Leadership
- Board of Directors
Our Approach
- Our Approach
- Scientific Publications
Pipeline
Investors & Media
Partnerships
Careers

Press Releases

Year

12.3.24

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

12.2.24

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

11.18.24

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

11.12.24

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

11.6.24

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

10.7.24

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

09.12.24

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

09.10.24

Terns Announces Pricing of Upsized $150.15 Million Public Offering

09.9.24

Terns Announces Proposed Public Offering

09.9.24

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Email Alerts
RSS Feeds
Print Page
Contact IR

TERNS
1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404 (MAP)
info@ternspharma.com
investors@ternspharma.com
media@ternspharma.com
Phone: +1 650-525-5535 Ext.101
Fax: +1 650-275-4254

About Us
Our Approach
Pipeline
Investors & Media
Partnerships
Careers
Contact Us

© 2024 Terns Pharmaceuticals, Inc. Privacy Policy